Multi-agent Chemotherapy (e.g., Methotrexate, Doxorubicin, Cisplatin, Ifosfamide)
Treatment for Malignant Neoplasm Of Bone And Articular Cartilage
Typical Dosage: Highly specific to regimen (e.g., Cisplatin 75-120 mg/m2, Doxorubicin 75-90 mg/m2, Methotrexate high-dose)
Effectiveness
80%
Safety Score
25%
Clinical Trials
500
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Highly specific to regimen (e.g., Cisplatin 75-120 mg/m2, Doxorubicin 75-90 mg/m2, Methotrexate high-dose)
Time to Effect
Weeks to months (during treatment cycles)
Treatment Duration
6-12 months typically
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$100,000
Monitoring:$20,000
Side Effect Mgmt:$60,000
Total Annual:$180,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODQALYs Gained
3.5
Outcome-Based Costs
Cost per Responder
$257,143
Cost per Remission
$360,000
Multi-agent Chemotherapy (e.g., Methotrexate, Doxorubicin, Cisplatin, Ifosfamide) Outcomes
for Malignant Neoplasm Of Bone And Articular Cartilage
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+70%
Remission Rate
+50%
Common Side Effects
Nausea/Vomiting
+80%
Myelosuppression (low blood counts, infection risk)
+90%
Fatigue
+85%
Hair Loss
+90%
Mucositis
+55%
Nephrotoxicity
+30%
Cardiotoxicity (e.g., Doxorubicin)
+3%
Neurotoxicity
+20%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov